3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
6
Neoplasms
5
Neoplasm Metastasis
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Vomiting
1
Stomatitis
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Alveolar Soft Part
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraproteinemias
1
Oncology Patients Receiving Chemotherapy
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Nausea
1
NSCLC
1
Mucositis
1
Mastocytosis, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Oncology Patients Receiving Chemotherapy
×
Diphenhydramine
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts